METAREM is a master protocol that encompasses multiple therapeutic sub-protocols, each involving distinct interventions. Accordingly, the description of the intervention will be specified within each for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 24 Feb 2026: Trial registered, NCT07431073
  2. 21 Aug 2026: Trial started, NCT07431073

The trials

NCT07431073: Immunotherapy Master Trial for Advanced Cancers

State
Under way
Phase
Phase 2
People
275 planned
Started
21 Aug 2026
Primary completion
Dec 2028
Arms
Single Arm immunotherapy in Advanced Metastatic Cancers
Results
None posted
  1. 24 Feb 2026: Trial registered
  2. 21 Aug 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.